Precision Medicine With Zibotentan in Microvascular Angina
Ключови думи
Резюме
Дати
Последна проверка: | 09/30/2019 |
Първо изпратено: | 07/04/2019 |
Очаквано записване подадено: | 09/18/2019 |
Първо публикувано: | 09/19/2019 |
Изпратена последна актуализация: | 10/21/2019 |
Последна актуализация публикувана: | 10/22/2019 |
Действителна начална дата на проучването: | 10/17/2019 |
Приблизителна дата на първично завършване: | 04/29/2022 |
Очаквана дата на завършване на проучването: | 11/29/2022 |
Състояние или заболяване
Интервенция / лечение
Drug: Zibotentan
Drug: Placebo
Фаза
Групи за ръце
Arm | Интервенция / лечение |
---|---|
Experimental: Zibotentan | Drug: Zibotentan 10mg OD Zibotentan |
Placebo Comparator: Placebo | Drug: Placebo Placebo |
Критерии за допустимост
Възрасти, отговарящи на условията за проучване | 18 Years Да се 18 Years |
Полове, допустими за проучване | All |
Приема здрави доброволци | Да |
Критерии | Inclusion Criteria: 1. Age >18 years. 2. Microvascular angina - as defined by COVADIS diagnostic criteria for microvascular angina. 3. Able to comply with study procedures. 4. Written informed consent. Exclusion Criteria: 1. Exercise tolerance >540 seconds in men and >430 seconds in women (i.e. actual exercise duration (s) achieved on the Bruce protocol commensurate with predicted), or, lack of anginal symptoms and/or ST-segment depression (0.1 mV) limiting exercise. 2. Non-cardiovascular exercise-limiting problem e.g. morbid (or severe) obesity (BMI ≥40.0 kg/m2) 3. Genotype not available 4. Women who are pregnant, breast-feeding or of child-bearing potential (WoCBP) without a negative pregnancy test and who are unwilling or unable to follow the reproductive restrictions and use highly effective contraception as defined in Appendix 3 of the protocol for the duration of the study treatment and 30 days after last dose of study drug. 5. Men who are sexually active with a WoCBP who are unwilling to use condoms or other highly effective methods of contraception for the duration of study treatment and for 14 weeks after last dose of study drug. 6. Heart failure (New York Heart Association Grade ≥II i.e. mild symptoms and slight limitation during ordinary activity) 7. Recent (<3 months) myocardial infarction 8. A history of epilepsy, other CNS adverse events, neurologic symptoms or signs consistent with spinal cord compression or CNS metastases. 9. Moderate or more severe renal impairment (GFR < 45 mL/min) 10. Liver disease with a Child-Pugh score of A (5-6 points) or higher 11. Participation in another intervention study involving a drug within the past 90 days or 5 half-lives whichever is longer (co-enrolment in observational studies is permitted). |
Резултат
Първични изходни мерки
1. EFFICACY - Exercise Testing (treadmill exercise time, seconds) [34 weeks]
Вторични изходни мерки
1. EFFICACY - Health Status QLQ (Seattle Angina Questionnaire) [34 weeks]
2. EFFICACY - Health Status QLQ (Illness Perception - Brief IPQ) [34 weeks]
3. EFFICACY - Health Status QLQ (Anxiety/depression - PHQ4) [34 weeks]
4. EFFICACY - Health Status QLQ (Treatment satisfaction - TSQM) [34 weeks]
5. EFFICACY - Health Status QLQ (EQ5D-5L) [34 weeks]
6. FEASIBILITY - Withdrawal Rate [34 weeks]
7. SAFETY - SAEs [34 weeks]
8. EFFICACY - Exercise Testing (time,sec to 1mm ST-depression) [34 weeks]
9. EFFICACY - Exercise Testing (maximum ST-segment deviation, mV) [34 weeks]
10. EFFICACY - Exercise Testing (Time (s) to 75% of max age-related heart rate during exercise) [34 weeks]
11. EFFICACY - Exercise Testing (Metabolic equivalent (METs) [34 weeks]
12. EFFICACY - Exercise Testing (DUKE Score) [34 weeks]
Други изходни мерки
1. EFFICACY - Pharmacodynamics (Exploratory) [34 weeks]
2. EFFICACY - Pharmacokinetics (Exploratory) [34 weeks]
3. EFFICACY - Angina Diary (Exploratory) [34 weeks]